Covid: Pfizer to send extra 50 mn vaccine doses to EU in second quarter

The European Commission currently has a portfolio of 2.3 billion doses from a half dozen companies and is negotiating more contracts.

Pfizer Vaccine, Coronavirus vaccine
Photo: Shutterstock
Reuters
2 min read Last Updated : Apr 14 2021 | 7:04 PM IST
EU Commission chief Ursula von der Leyen announced plans Wednesday for a major contract extension for COVID-19 vaccines with Pfizer stretching to 2023.
 
In a sign of confidence in a company that has been a mainstay of Europe's vaccination drive so far, von der Leyen said the EU will start negotiating to buy 1.8 billion doses of the Pfizer-BioNTech vaccine through 2023.
 
Von der Leyen expressed full confidence in the technology used for the Pfizer-BioNTech vaccine, which is different from the technology behind the Oxford-AstraZeneca vaccine.
 
“We need to focus on the technologies that have proven their worth,” von der Leyen said.
 
Pfizer-BioNTech plans to provide the EU with an extra 50 million dozes in the 2nd quarter of this year, on top of 200 million doses already earmarked for the bloc. The deliveries will be especially welcomed by the EU's 27 member nations considering supply delays and concerns over rare blood clots potentially linked to the Oxford-AstraZeneca vaccine.
 
Denmark decided Wednesday not to resume use of AstraZeneca COVID-19 vaccine after putting it on hold last month following reports of rare blood clots in some recipients. The bulk of the shots given in the Scandinavian country so far have been the Pfizer-BioNTech vaccine.
 
The European Commission currently has a portfolio of 2.3 billion doses from a half dozen companies and is negotiating more contracts.
 
The planned negotiations with Pfizer left in the middle what the EU would do about any new contracts with AstraZeneca, which has had massive delivery problems during the first quarter and expects to send far fewer vaccines than its contract with the EU called for during the second quarter.
 
The European Commission said in a statement, “We keep all options open to be prepared for the next stages of the pandemic, for 2022 and beyond. We can, however, not comment on contractual issues.” Von der Leyen, however, showed her full support for Pfizer-BioNTech, with the announcement for the massive order.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

Next Story